This inventor holds 1 USPTO granted patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Université Cote D'azur. Active years: 2022.
Company Filing History:
1 out of 5,383 
1 out of 1,853 
1 out of 25 Years Active: 2022
Title: Emile Jaune: Innovator in Cancer Treatment
Introduction
Emile Jaune is a notable inventor based in Saint-Cannat, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on the creation of biguanide derivatives, which have potential applications in treating various forms of cancer, particularly melanoma.
Latest Patents
Emile Jaune holds 1 patent for his invention titled "Biguanide derivatives and their rearrangement products for use in the treatment of cancer." This patent discloses biguanide derivatives of a specific formula and their rearrangement products. The compounds developed by Jaune are intended for use in methods for treating cancer, showcasing his commitment to advancing medical science.
Career Highlights
Throughout his career, Emile Jaune has worked with esteemed institutions such as the Centre National de la Recherche Scientifique and the National Institute of Health and Medical Research. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Emile Jaune has collaborated with notable colleagues, including Rachid Benhida and Stephane Rocchi. These partnerships have enriched his research and expanded the impact of his work in the scientific community.
Conclusion
Emile Jaune's innovative contributions to cancer treatment through his patented biguanide derivatives highlight his role as a significant inventor in the medical field. His dedication to research and collaboration continues to inspire advancements in cancer therapies.